The Dynamics of EBV Shedding Implicate a Central Role for Epithelial Cells in Amplifying Viral Output by Hadinoto, Vey et al.
The Dynamics of EBV Shedding Implicate a Central Role
for Epithelial Cells in Amplifying Viral Output
Vey Hadinoto
., Michael Shapiro
., Chia Chi Sun, David A. Thorley-Lawson*
Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts, United States of America
Abstract
To develop more detailed models of EBV persistence we have studied the dynamics of virus shedding in healthy carriers. We
demonstrate that EBV shedding into saliva is continuous and rapid such that the virus level is replaced in #2 minutes, the
average time that a normal individual swallows. Thus, the mouth is not a reservoir of virus but a conduit through which a
continuous flow stream of virus passes in saliva. Consequently, virus is being shed at a much higher rate than previously
thought, a level too high to be accounted for by replication in B cells in Waldeyer’s ring alone. Virus shedding is relatively
stable over short periods (hours-days) but varies through 3.5 to 5.5 logs over longer periods, a degree of variation that also
cannot be accounted for solely by replication in B cells. This variation means, contrary to what is generally believed, that the
definition of high and low shedder is not so much a function of variation between individuals but within individuals over
time. The dynamics of shedding describe a process governing virus production that is occurring independently #3 times at
any moment. This process grows exponentially and is then randomly terminated. We propose that these dynamics are best
explained by a model where single B cells sporadically release virus that infects anywhere from 1 to 5 epithelial cells. This
infection spreads at a constant exponential rate and is terminated randomly, resulting in infected plaques of epithelial cells
ranging in size from 1 to 10
5 cells. At any one time there are a very small number (#3) of plaques. We suggest that the final
size of these plaques is a function of the rate of infectious spread within the lymphoepithelium which may be governed by
the structural complexity of the tissue but is ultimately limited by the immune response.
Citation: Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA (2009) The Dynamics of EBV Shedding Implicate a Central Role for Epithelial Cells in Amplifying Viral
Output. PLoS Pathog 5(7): e1000496. doi:10.1371/journal.ppat.1000496
Editor: Samuel H. Speck, Emory University, United States of America
Received February 11, 2009; Accepted June 3, 2009; Published July 3, 2009
Copyright:  2009 Hadinoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Public Health Research Grants CA65883, AI18757 and AI062989. MS was supported by Public Health Research Grant
#1K25AI79404-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: david.thorley-lawson@tufts.edu
. These authors contributed equally to this work.
Introduction
Epstein-Barr virus is a human herpes virus that has the capacity
to transform B lymphocytes in culture into continuously
proliferating lymphoblasts [1,2]. However, it persists in vivo in
resting, germinal center derived memory B cells [2,3] that we refer
to as mBLat [4]. The generally accepted model of viral persistence
holds that the virus uses its transforming abilities to activate newly
infected resting B cells and then latency associated viral proteins
provide surrogate signals to allow the newly activated cells to
differentiate through the germinal center into the memory
compartment [1–3].
EBV is clinically important because of its involvement in several
human cancers including Hodgkin’s disease, Burkitt’s lymphoma,
immunoblastic lymphoma in the immunosuppressed and naso-
pharyngeal and gastric carcinomas [5,6]. The ability to immor-
talize B cells and the fact that EBV encodes for several potential
oncogenes [7,8] provides one source of risk for EBV associated
tumorigenesis. A second factor in EBV associated cancer
susceptibility is that the virus establishes a persistent infection
resulting in lifetime exposure of the host to infectious virus and
viral gene products. The tissue that is most exposed to infectious
virus is the epithelium of the tonsils and nasopharynx since this is
where the virus is replicated and shed into saliva for horizontal
spread of the infection to new hosts [9,10]. Long term exposure to
infectious virus in this anatomical region may be an important risk
factor in the development of the EBV associated cancer
nasopharyngeal carcinoma.
Although virus shedding is a hallmark of persistent infection it
has not, to our knowledge, been systematically studied in healthy
carriers of the virus by sensitive, quantitative PCR techniques.
Currently, therefore, there is a dearth of systematic quantitative
data on viral shedding that would allow the formulation and
testing of models of virus production. Consequently it remains
unclear what regulates the levels of virus shedding in saliva. Some
previous studies have used a biological assay to detect EBV
[10,11], based on its ability to transform B cells in culture.
However, in our hands this assay is unreliable, insensitive and not
quantitative. Others have used relatively insensitive and therefore
non-quantitative PCR approaches to assess virus shedding
particularly during acute infections e.g. [12–15]. Perhaps not
surprisingly these studies have produced conflicting results. For
example one study concluded that virus shedding was correlated
with the levels of infected B cells in the blood whereas a second
study found no such correlation [11,13]. Generally however, it
appears to be the view in the field that individuals can be classified
by relative levels of shedding into high, intermediate and low
shedders where virus shedding is sporadic and often undetectable
PLoS Pathogens | www.plospathogens.org 1 July 2009 | Volume 5 | Issue 7 | e1000496[5,11]. Since these conclusions are based on non-quantitative and
insensitive assays it is difficult to assess and reconcile these
conclusions. For example, it is unclear if failure to detect virus is
due to its absence or simply a function of the insensitivity of the
assays used.
We have previously developed sensitive, quantitative PCR
techniques for detecting EBV DNA [4,16] and EBV gene products
[17,18]. Using these assays we showed for the first time that the
levels of virus infected cells in the blood of healthy carriers were
individual specific and highly stable over long periods of time
(years) [19]. In this study we have set out to apply this same
approach to the dynamics of virus shedding into saliva by healthy
carriers of the virus and use this data to develop and test potential
models of EBV shedding. We find that the overall dynamics
strongly implicate the epithelium as a site where virus is amplified
prior to shedding.
Results
High levels of virus shedding by healthy carriers of EBV
Traditionally the levels of virus in saliva have been assessed at a
single point in time by having subjects gargle with a defined
volume of fluid. The amount of virus in the gargle is then
measured either with a biological assay [10,11], based on
transformation of B cells in culture or by PCR for the copy
number of viral genomes [12–15]. However, this type of analysis is
static and provides no kinetic information about the rate of virus
production. Therefore in our first series of studies we sought to
measure the rate of virus production by first rinsing out all of the
virus in saliva and then measuring the rate at which the virus
returned. To this end volunteers were asked to rinse and gargle
sequentially with 5 cc of fluid and the levels of virus measured with
a quantitative DNA PCR technique that can detect a single copy
of the viral genome. To our surprise sequential rinses failed to
deplete the levels of virus in the saliva even when up to 8 rinses in a
row were tested (Figure 1 shows the results for two subjects who
were at the lower and upper levels respectively of shedding at the
Author Summary
Epstein-Barr virus is a human pathogen associated with
several human cancers that nevertheless persists benignly
as a latent infection in the majority of adults. EBV
persistence is characterized by the presence of latently
infected cells in the blood and the shedding of virus into
saliva. We present the first systematic quantitative analysis
of virus shedding. We show, contrary to what was
previously thought, that shedding is continuous and at a
high level for all subjects tested. This constant presence of
infectious virus may be a crucial risk factor in the
development of the EBV-associated tumor nasopharyngeal
carcinoma. Unlike infected cells in the blood, which are
maintained at very stable levels for years, we show that
virus shedding is highly variable such that at any time any
individual may be a relatively high or low shedder. We
have analyzed these dynamics mathematically and with a
simple simulation model. We find that they can be
explained by a simple exponential function which we
hypothesize is the expansion of 1–3 plaques of epithelial
cells.
Figure 1. The level of virus in saliva is stable and cannot be eliminated by repeated washing. Two subjects were asked to rinse
repeatedly with 5 ml of fluid and the viral genome copy number in the rinses estimated by EBV specific DNA PCR for the W repeat sequence of the
viral genome. Note that even after 8 sequential rinses a similar level of virus was detected. The calculation to the right is based on an average time
between rinses of approximately 2 minutes and a final volume of saliva rinse of 5 ml.
doi:10.1371/journal.ppat.1000496.g001
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attempted to wash out the virus first with 4 sequential 25 ml rinses
and then with 2 more 25 ml rinses. After each attempt a
subsequent 5 ml rinse had essentially the same amount of virus as
the initial rinse (see Figure S1). We reached the unexpected
conclusion therefore that virus is continuously being shed into
saliva at such a high rate that the virus removed by rinsing was
already replaced by the time we retested the saliva (,2 minutes).
To our knowledge this is the first time that this simple technique of
sequential sampling has been performed and leads us to the
conclusion that the rate of virus production is much greater than
had been previously thought. Included in Figure 1 is the estimated
virus shedding per day for the two subjects analyzed which lead to
the conclusion that 5610
5 and 10
8 genomes are being produced
by Subject 1 and 2 respectively per rinse or 3.2610
8 and 6610
10
per day.
Estimated cell number required for viral shedding
The time course of virus production by individual cells in
culture has been estimated to be approximately 24 hours from
initiation of lytic gene transcription to the release of infectious virus
[20]. However, to our knowledge no-one has attempted to
accurately estimate the viral burst size. We have done this
multiple times for both B cell lines (Akata and B95-8 ) and
epithelial cell lines (HONEAkata and AGSBX1). The fraction of
cells replicating the virus was assessed by flow cytometry after
staining for the viral capsid antigen 48 hours post stimulation. The
amount of virus released was measured by performing EBV
specific DNA PCR on the cell culture supernatants at 72 hours.
The results of this analysis are summarized in Table 1. For the B
cell lines the average production was quite similar despite their
very different origins or whether or not the virus was chemically
induced. Similarly for the two epithelial cell lines. However,
production from the epithelial cells (6.2610
5genome copies per
cell) was about ten fold higher than from the B cells (7.3610
4
genome copies per cell)However less than 10% of these genomes
appeared to be intact virions based on resistance to DNase
digestion. (Table 1).
Using a burst size of 7.3610
4 genome copies per B cell and
assuming a 24 hour lytic cycle we can estimate that the shedding
by Subjects 1 and 2 would require viral production from 4.4610
3
and 8.2610
5 B cells per day, respectively. This is several logs
higher than the value we have measured previously for the
number of lymphocytes in Waldeyer’s ring that complete virus
replication which we estimate to be extremely small averaging 0.5
cells per day with an upper bound ,100 (Box 1). Therefore, we
may conclude that there are insufficient B cells replicating EBV in
Waldeyer’s ring to account for the levels of virus being shed into
the saliva (see also Box 1 and Discussion).
Stability of virus shedding over time
Figure 1 demonstrates that virus shedding into saliva was quite
stable at least over short time periods. When we measured
shedding in the same individuals over hours or days we saw a
similar degree of stability (Figure 2). However, when we tracked
them for longer periods (up to one and a half years) we saw a
strikingly different result (Figure 3) with fluctuations over 4–5 logs.
To test if this variation was a consequence of variable
‘‘aggressiveness’’ in the sampling procedure over time we also
performed PCR for an internal cellular control gene (bcl-2). When
the levels of cellular DNA in saliva were tracked over the course of
three months in three individuals the largest variation in recovery
we obtained was 40 fold compared to 1.5610
4 fold in virus
shedding in the same samples (not shown) This indicates that
sampling variation was not the source of the variation in virus
shedding that we observed. Unlike virus shedding we have shown
previously that the level of latently infected memory B cells (mBLat)
in the blood of healthy carriers is extremely stable over years [19]
and even decades (DTL unpublished observations) in healthy
carriers. To confirm that this was true for the subjects and times
studied here we measured the levels of mBLat in their blood at the
same times we measured virus shedding. As expected the levels of
mBLat in their blood were stable over the entire time period
(Figure 3).
We conclude that although virus shedding within an individual
is quite stable over short time periods (hours/days) it is highly
variable over the course of months and years. As described above
we have previously shown that the number of B cells completing
viral replication per day in Waldeyer’s ring is small therefore it is
also not possible to account for the variation in shedding within an
individual simply in terms of variation in the number of B
lymphocytes replicating the virus in Waldeyer’s ring at any one
time (see also Discussion).
Table 1. Estimated viral burst size for two independent B and epithelial cell lines.
Cell line Cell type n Genome copies/cell SD Virions/cell
{ SD
Akata+PMA/Iono* B 5 6.8610
4 3.5610
4 2.1610
3 1.5610
3
B95-8+PMA* B 6 1.0610
5 9.2610
4 6.3610
3 3.4610
3
B95-8 B 6 6.2610
4 5.7610
4 5.9610
3 5.7610
3
Average B 15 7.3610
4 4.8610
3
AGSBX1+TPA/BA* Epith. 4 2.6610
5 1.0610
5 2.3610
5 9.7610
4
AGSBX1 Epith. 3 1.4610
5 2.8610
4 1.7610
5 6.0610
4
Hone1Akata+TPA/BA* Epith. 4 1.4610
6 3.4610
5 2.2610
5 1.2610
5
Hone1Akata Epith. 3 6.8610
5 3.6610
5 4.3610
4 3.1610
4
Average Epith. 14 6.2610
5 1.7610
4
*Induced by PMA, PMA+Ionomycin or PMA+butyric acid.
n=number of measurements.
For details see Materials and Methods.
{Virion copy number was defined as the portion of viral DNA that was resistant to DNase treatment under conditions where .99% of cell free DNA was digested: 1 U/ul
for 30 min at room temperature (see Materials and Methods, Table 3 and Figure S3).
doi:10.1371/journal.ppat.1000496.t001
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shedders
We have analyzed the data from Figure 3 to see if it contained
an underlying structure that might shed light on the dynamics and
mechanism of virus shedding. Most revealing was the cumulative
distribution function (CDF). The CDF (http://en.wikipedia.org/
wiki/Cumulative_distribution_function) describes the probability
distribution of a real-valued random variable X, in this case the log
value of virus shedding. The CDF of a given value of X is the
proportion of the measurements whose value is equal to or less
than X. As the value of X increases, the CDF of X increases from
0 to 1. So for example the median for a set of measurements has a
CDF of 0.5. The CDF for the three subjects in Figure 3 are
presented in Figure 4A. Here the log values for virus shedding are
plotted cumulatively from lowest to highest and thus appear as
steps, and the number of data points are normalized by setting the
total to equal 1. Strikingly the distributions were essentially linear
for all three data sets. To see if this was a coincidence unique to
this particular experiment or a general property of virus shedding
we analyzed a large data set collected from 8 different subjects
over an extended period of time (up to two years) which also
included a much larger number of data points for subjects 1–3
(essentially additional points for which we did not have matching
blood level measurements). A summary of all this data, which
includes a total of 165 positive data points and 8 time points where
no virus shedding was detected, is presented in box plots in
Figure 5A and in Table S1. The time points where no virus
shedding was detected are not included in the box plots but are
indicated by the asterisks in Figure 5A. We are confident that there
was no viral DNA present in the saliva samples at these times
because our PCR technique can reproducibly detect a single copy
of the viral genome and positive detection of a control cellular
sequence (bcl-2) confirmed the sampling process was normal.
From Figure 5A it is apparent that a large range of variation is a
ubiquitous feature of virus shedding with most subjects demon-
strating around a 4 log range, the largest being 5.5 logs (subject
#9) and the smallest 3.3 logs (subject #8). Table S1 shows the
mean, median and standard error of the mean (SEM) for the
measurements on all 8 subjects Although the mean and median
values only varied by about two orders of magnitude between the
8 subjects, the SEM within each individual ranged over 4–6 orders
of magnitude indicating the extent to which the range of virus
shedding overlapped between individuals and that the shedding
profiles are not statistically different between different individuals.
Most revealing though was the CDF analysis of this data shown in
Figure 4B which confirmed the original result with the limited data
set from subjects 1–3. For all 8 subjects, a linear relationship was
observed between the log value of the shedding and its cumulative
probability of occurring. Put another way the probability of
(log)shedding was equal for all levels over a several log range. This
is the expected result when a simple exponential process, such as
growth or infectious spread, is sampled randomly over time. In
Figure 6 we show the best fit lines to the data from all 8 Subjects
(from Figure 4B) and in Table 2 we describe the properties of these
lines including the slopes and the results of linear regression
analysis (adjusted R
2). The R
2 value for all 8 subjects was
extremely high ($0.88) indicating that the data closely approxi-
mates a linear relationship. In addition it is apparent that the
slopes of the lines are very similar for all 8 subjects although the
lines were spread over a wide range encompassing .2 logs
(compare Subject 2 and 9 in Figure 4B and the x intercepts for all
8 subjects in Figure 6).
These results provide several important conclusions. Contrary
to what has been claimed previously [11], there are no distinct
high, intermediate or low virus shedders. So although on average
for example subject #9 is low, subject #3 medium and subject #2
high, multiple measurements over extended time show these
assignments to be relatively meaningless. Rather at any one time
an individual might be high, low or intermediate. Furthermore the
underlying process behind the variation in shedding is a simple
exponential that is either arrested randomly, and then held stable,
or observed at random times. This exponential is initiated over a
range of shedding at levels that are subject specific (lines are
displaced over .2 logs in the CDF plots) but whose subsequent
growth rate is subject independent (slopes are similar in the CDF
plots). We suggest that these events are the exponential expansion
of infected epithelial cell plaques (see Discussion).
Box 1. Neither the absolute levels nor the
variation over time of virus shedding can be
accounted for by B cells alone replicating the
virus in Waldeyer’s ring.
The frequency of infected B cells in Waldeyer’s ring from a
large cohort of healthy carriers varies between 1/10
7 and
1/10
4 [27].
Assuming 10
10 B cells in the entire Waldeyer’s ring then
thereareatmost10
6infectedBcells.Wehavemeasuredthe
fraction of infected B cells replicating the virus per day
(assuming a 24 hr lytic cycle) to be no more than 0.5%* [26].
Therefore, there are at most ,5610
3 cells replicating the
virus. A.
Alternatively: In a screen of palatine tonsils we detected
viral replication in 8 out of 20 subjects [26]. Applying
Poisson statistics this suggests that on average there are
0.51 cells per Palatine tonsil or 6.5 per Waldeyer’s ring
replicating the virus at any time. B.
However we have shown previously that only 10% at most
of cells that initiate viral replication in Waldeyer’s ring
complete it.
Therefore at most only ,5610
2 B cells complete viral
replication per day (from line A) with an average of only
0.65 per day (from line B).
From Table 1 the burst size per B cell=7.3610
4 genome
copies.
Therefore, the maximum amount of virus that could be
produced by B cells in Waldeyer’s ring
=5 610
26(7.3610
4) =3.6610
7 genome copies per
day C.
And the average per day
=0.656(7.3610
4) =4.7610
4 genome copies per day
From Figure 5 the range of shedding for 8 healthy carriers
=5 to 2610
7 genomes/ml/rinse
If arinse takesonaverage2 minutesand contains 5 mlthen
the range of shedding per day for 8 healthy carriers
=(5 to 2 610
7 genomes/ml)65m l / r i n s e 630rinses/hour6
24 hours
=1.8610
4 to 7.2610
10 genome copies per day D.
Comparison of line C and line D reveals that there is a ,3
log discrepancy between the maximum level of virus
shedding that could be accounted for by B cells and the
upper limit that we have actually measured.
*N.B. This value is based on estimates from 2 tonsils that
had the highest signal for expression of the viral lytic gene
BZLF1 therefore it represents the upper limit on the % of
infected cells replicating the virus.
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number of independent events is very small
A straight line relationship between the log of shedding and the
cumulative number of observations (the CDF) implies that the
number of these putative plaques must be very small otherwise the
shedding from the largest plaques would always dominate and the
plot would become non-linear. This is demonstrated in Figure 6
and Figure S2 where we have performed a simulation of this
process for various numbers of plaques (For details of the
simulation see Text S1 – ‘‘Empirical CDF of shedding suggests
there are at most 3 plaques at any one time.’’). In this simulation
various numbers of plaques are seeded randomly, allowed to grow
exponentially and then sampled at 20 random points in time. This
produces a simulated CDF of log shedding from which an adjusted
R
2 can be calculated. As the number of plaques increases the plots
tend to become steeper and increasingly skewed away from linear.
We next used the simulation to ask: what is the probability of
obtaining our actual data set with different numbers of plaques?
To achieve this we simply repeated the simulations shown in
Figure S2 100 times for each plaque number, performed a linear
regression analysis to calculate the adjusted R
2 for each run and
then plotted these values as a CDF for the adjusted R
29s (Figure 7).
We can then ask: what is the probability of obtaining the adjusted
R
2 values we have observed for our 8 subjects with simulations
involving different numbers of plaques. We have used three
different criteria. First, what is the probability of obtaining an
adjusted R
2 value 7 out of 8 times in a row that is higher than the
lowest value we have observed with our 8 subjects? Second what is
the probability of obtaining8 values with a median value equal to or
higher than the median value for our 8 subjects? Third, what is the
probability of obtaining 8 values as high as or higher than the lowest
value we have observed with our subjects. This calculation revealed
p values of ,0.05 for $2 plaques, $3 plaques and $4 plaques for
the three methods respectively. Taken together these analyses
suggest that the shedding of EBV in healthy carriers is the result of a
very small number, #3, of these putative epithelial plaques.
We can also derive an estimate of the average plaque number in
a completely different and independent way since we have
observed that virus was not shed on 8 occasions out of the total
173 measurements we have taken. From simple Poisson statistics
we can calculate that if we find no evidence of infectious plaques
8/173 times then on average there must be ,3 such plaques, a
value which is in very close agreement with the prediction (#3) of
the CDF analysis.
In conclusion it appears that EBV shedding is the consequence
of an exponential process that is either terminating or being
observed randomly and that there are #3 of these events
occurring at any given time.
Figure 2. Virus shedding is stable over hours and days. The bars represent the levels of viral DNA found in saliva at the times indicated. For
details see Legend to Figure 1. N.B. For the data in the lower right panel single samples were taken on day 1 and 2 but two samples taken on days 3
and 8, one in the morning(am) and one in the evening (pm).
doi:10.1371/journal.ppat.1000496.g002
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mBLat in the blood within or between individuals
As noted above the levels of mBLat in the blood of healthy
carriers of EBV is stable over long periods of time ([19] and
Figure 3) and we have now shown conversely, that virus shedding
is extremely variable over similar time spans. Therefore there is no
correlation within individuals between virus shedding and levels of
infected cells. In Figure 5B we have plotted the mean values from
Table S1 versus the frequency of mBLat in the circulation for all
subjects studied and it is apparent that there is also no correlation
between the levels of mBLat in the blood and the amount of virus
shed into saliva between individuals. (The same result holds true if
the median is plotted, not shown).
One possible explanation for the lack of correlation between
shed virus and the levels of mBLat in the blood is that PCR does
not distinguish intact virions from non-infectious viral DNA. To
evaluate this we assessed the DNase sensitivity of viral DNA in
saliva (see Figure S3) for an example of such an experiment). We
found that most of it was resistant; consistent with being in intact
virions, whether we tested raw saliva or the supernatant after
clarification by centrifugation (Table 3). This was much higher
than for the 2 cell lines we tested Akata and B95-8 (only 10–20%
resistant) suggesting that virions shed into saliva are more
efficiently packaged than in the cell lines. When we tracked the
levels of DNase resistant material in raw or clarified saliva we
again saw a 4 to 5 log variation over extended periods of time
(Figure 8) and no correlation with the level of mBLat (Figure S4).
The other possible explanation for our failure to find a
correlation between shed virus and mBLat was that PCR measures
all virions irrespective of their infectivity and it has been suggested
that a large fraction of virions in saliva are bound by neutralizing
antibody [21]. To test this possibility we assayed the amount of
viral DNA that would bind specifically (as judged by the failure to
bind the T cell line Jurkat and the ability to be blocked with anti-
gp350 neutralizing antibody 72A1 – not shown) to a B cell line. As
shown in Table 4 in two separate experiments despite repeated
absorptions (up to 6 times) only ,5% of the viral DNA in saliva
could bind the B cell line Akata. However, when we tested the
amount of Akata binding activity in saliva over an extended time
period we again found that the levels varied by approximately 4 to
5 logs and that there was no correlation with the levels of mBLat in
the peripheral blood (Figure S5).
Figure 3. Virus shedding but not levels of infected cells vary by 4 to 5 logs over the course of months/years. The amount of virus shed
in saliva and the frequency of latently infected mBLat in the blood were measured concomitantly in three individuals over the course of 500 days.
Note that virus shedding varies over 4 to 5 logs whereas the frequency of mBLat varies by less than a single log.
doi:10.1371/journal.ppat.1000496.g003
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In this paper we have described detailed kinetics of EBV
shedding in the saliva of healthy carriers of the virus. We have
employed a sensitive and quantitative DNA PCR assay that can
reliably detect a single copy of the viral genome. Using this assay
we show for the first time that EBV positive individuals
continuously shed EBV such that the saliva reservoir is completely
replaced in ,2 minutes. This is consistent with studies showing
that a normal individual swallows on average once every
2 minutes (www.uiowa.edu/ ˜c003236/indexS1L1a.html). Thus
the mouth is not a reservoir of virus but a conduit through which
a continuous flow stream of virus passes in saliva (Figure 9). Over
the course of several months to a year the level of shedding by a
given individual varies by 3.5 to 5.5 logs. Thus contrary to what is
currently thought [11] there is no clear distinction between low,
intermediate or high shedders of EBV. In fact shedding changes so
much over time that most of the variation between high and low
occurs within an individual not between individuals. If a cohort of
individuals are only measured over the course of a few days some
will be low, some intermediate and some high, but the
classifications will change over time. For example in Figure 3
Subject 1 might be classified as high (10
6 to 10
8 per ml) on day 300
or low (10
2 to 10
4 per ml) on day 325 and intermediate (10
4 to 10
6
per ml) on day 500 whereas Subject 2 would be high on day 50,
low on day 300 and intermediate on day 325. This point is
confirmed by the CDF analysis which demonstrates that an
individual has an equal probability of shedding at any level (log
values) from high to low.
Previous studies using either a biological assay [22,23] or PCR
[24,25] to detect the virus have reported that 10 to 70 percent of
EBV positive individuals shed detectable virus. In this study we
took 173 measurements over time on 8 different EBV positive
individuals and consistently found all 8 to be positive with only 8/
173 negative readings. Unlike previous studies we can be confident
that there was no viral DNA present in the saliva samples at these
times because our PCR technique can reproducibly detect a single
copy of the viral genome. Therefore, we did not detect an EBV
positive individual who was consistently a non-shedder. The much
higher rate of success we obtained no doubt reflects that the assays
used before were considerably less sensitive. We observed similar
discrepancies previously when assessing the prevalence of EBV in
peripheral blood B cells. Earlier reports had suggested a wide
range of detection based on PCR or a biological assay. However,
application of our DNA PCR assay revealed that 100% of EBV
seropositive individuals had infected cells in their blood 100% of
the time and indeed the levels were very stable and specific to each
individual [19]. These studies on viral loads in saliva and blood B
cells demonstrate that performing precise, sensitive and systematic
quantitative studies can provide consistent and novel insights into
EBV biology.
Surprisingly the main conclusions of our studies on viral
shedding point to the potential importance of epithelial cells in
EBV replication and shedding. This is because neither the
Figure 4. Cumulative distribution function (CDF) for the shedding data. (A) The log10 values for the shedding data in Figure 3 are plotted
cumulatively from lowest to highest against the normalized number of data points. Each step up represents a data point. Thus the extreme left point
on each graph represents the lowest value for which there is only one data point, the next step up represents the second lowest point and so on till
the last most extreme right point represents the highest value and therefore includes, cumulatively, all of the data points. (B) Cumulative distribution
function (CDF) for all the shedding data summarized in Figure 5A.
doi:10.1371/journal.ppat.1000496.g004
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have observed can be accounted for by B cells alone replicating the
virus in Waldeyer’s ring [26]. In Box 1 we have attempted to
estimate the amount of virus being shed from Waldeyer’s ring by B
cells. This calculation is based on the number of infected B cells in
Waldeyer’s ring from measurements on a large cohort of normal
subjects [27], our previously published estimates of the fraction of
infected B cells that completes viral replication at any time in
Waldeyer’s ring [26] and the viral burst size as estimated in the
current study. From this calculation we can see that there is ,3 log
discrepancy between the absolute maximum amount of virus that
could be produced by B cells in Waldeyer’s ring and the actual
levels we have measured in saliva. Therefore it is highly unlikely
that B cells alone can account for the levels of virus shedding we
have observed. Besides the absolute levels of virus shedding, the
range (3.5 to 5.5 logs) we have observed over time in any given
healthy carrier is also too large to be accounted for by B cells alone
replicating the virus since we estimated previously that at most
,100 B cells complete EBV replication in Waldeyer’s ring at any
one time ([26] and Box 1). This could only yield at best ,2 logs of
variation, again implicating a second site of EBV replication.
What/where could this cell type be? Recently the possible role of
epithelial cell infection in EBV biology has again been raised.
Infected epithelial cells have been detected in cultures of primary
tonsil epithelium [28], EBV has been shown to have a cluster of
virion glycoproteins (gH and gL) that mediate epithelial cell
infection [29,30] and EBV is found in the epithelial cells of
nasopharyngeal carcinoma [31] (where the virus is latent) and oral
hairy leukoplakia [32] (where the virus is lytic). Furthermore, the
virus in saliva is high in the glycoprotein gp42. This glycoprotein
binds to MHC Class II and is usually depleted in virions that
emerge from B cells suggesting that the virus in saliva originates
from a non-B cell [33]. This is consistent with a model whereby
virus released from B cells infects the tonsil epithelium where it
replicates and becomes amplified prior to shedding into saliva. To
investigate this possibility we have estimated the potential amount
of virus produced from epithelial cells in Waldeyer’s ring (Box 2).
This calculation was based on published values for the surface area
of epithelial cells in Waldeyer’s ring [34], our estimate of the
density of an epithelial cell monolayer [28], our published
estimates of the frequency of epithelial cells replicating EBV in
cultures of primary tonsil epithelium [28] and the viral burst size of
epithelial cells as estimated in this study (Table 1). From this
calculation it is apparent that epithelial cell infection could account
for the levels of shedding we have seen.
The CDF analysis provides considerable insight into how
epithelial infection could account for the shedding we have
observed. We have seen that the CDF for the log of shedding is
close to linear for each subject. A linear CDF occurs when a
process grows exponentially with respect to time over a fixed life
span and is either sampled at random or arrested and held
constant at random times. We can discount the first hypothesis
(sampling) because virus shedding is stable over short periods of
time and is therefore not simply an exponentially growing
function. Rather it appears to be an exponentially growing
function that is stopped at random, stays stable for several hours/
days and then dissipates. Since virus shedding cannot be
accounted for by B cells we propose that this function is the
growth of infected epithelial plaques that are seeded by virus
released from B cells and that these plaques become arrested in
their spread randomly over time. This would be the EBV
equivalent of HSV reactivating in a ganglia traveling to the skin
and infecting the surrounding fibroblasts leading to the production
of a herpes lesion. Assuming a burst size of 6.2610
5 for epithelial
cells (Table 1) the range of virus shedding/ml saliva rinse we have
observed in Figure 5A and Table S1 (522610
7 genomes yields
[522.10
7]65 ml/rinse630 rinses/hour624 hrs=1.8610
4 to
7.2610
10 genomes per day) would derive from ,1t o1 0
5
epithelial cells releasing virus per day. This implies that the
plaques range in size anywhere from 1 cell (which could simply be
the original seeding B cell) up to 10
5 epithelial cells.
As demonstrated in the results section the linear nature of the
CDF for our subjects constrains the number of these plaques to be
#3 at any time. However if this is true why do we not see periods
of simple exponential growth in our measurements? When we
perform measurements at ever shorter time periods we eventually
encounter stability not exponential growth. This observation puts
two constraints on the model, The first is that the number of
plaques is usually .1 such that a plaque in its stable state is usually
masking part or all of the growth phase of a new plaque(s) and
second that the maximum time of growth for the plaque must be
less than the length of time they are stable which we have seen is
up to 7 days (For a detailed discussion of this issue see Text S2 –
‘‘Why we have not observed the growth phase.’’. This places the
Figure 5. There is no such entity as a consistently high or low
shedder of EBV and no correlation between the levels of
shedding and the frequency of infected mBLat in the blood. (A)
Shows the range of virus shedding in 8 individuals over months/years.
Note that shedding varies between 3.5 and 5.5 logs. Red bars=the
median, black box=25th and 75
th percentile, dashed line=the range,
N=the number of independent positive measurements. * - the number
of asterisks indicates the number of time points when no virus
shedding was detected. (B) Shows the mean values for the data shown
in A. plotted versus the frequency of infected mBLat (FOI) in the
peripheral blood for each subject.
doi:10.1371/journal.ppat.1000496.g005
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expansion followed by ,7 days of stability.
The two obvious candidates for the exponential function
predicted by the CDF are growth of infected epithelial cells or
infectious spread of virus. If growth were responsible it assumes a
model where new infection produces latently infected epithelial
cells that continue to proliferate and generate cells producing virus
at the same time until some event, presumably the immune
response halts the growth. Latent infection of tonsil epithelium has
been documented [28] and this type of scenario was proposed
many years ago based on analogy to the HPV system [35] where
the differentiation of latently infected cells triggers viral replication.
In support of this idea, differentiation dependent replication of
EBV has been documented in both epithelial [36] and B cells [26].
However, we do not favor this model because it would take two to
three weeks to achieve the maximal plaques size of 10
5 cells
(assuming the cells divide once every 24 hours). As we have seen
the data constrains the growth phase to be no more than a week
and in addition it seems highly unlikely that such a structure could
evade the immune response for such a long period of time.
The alternative hypothesis is that the plaques simply grow by
infectious spread. Precedence for this idea comes from in vitro
infection of polarized tonsil epithelium which has been shown to
readily generate plaques of cells replicating the virus [37,38] and
in vivo from the pathological entity oral hairy leukoplakia which
arises in the immunosuppressed and essentially consists of very
large plaques of epithelial cells replicating EBV [32]. In this model
a single epithelial cell releasing virions sufficient to infect on
Figure 6. Linear regression analysis of the data in Figure 4B. The CDFs for the 8 subjects are plotted individually as data points rather than as
steps with the best fit straight line from linear regression analysis. Slopes and adjusted R
2 values are given in Table 2. Blue line=the best fit straight
line from the linear regression analysis. Red circles=the data points; green circles=the residuals i.e. the difference between each data point and the
value given by the line.
doi:10.1371/journal.ppat.1000496.g006
Table 2. Slope and R
2 values for the best fit lines shown in
Figure 6.
Subject Slope Adj R
2
1 0.25 0.94
2 0.22 0.98
3 0.22 0.96
6 0.23 0.94
8 0.28 0.97
9 0.17 0.94
11 0.18 0.95
13 0.25 0.88
doi:10.1371/journal.ppat.1000496.t002
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maximum plaque size in less than a week. However, there is a
geometric constraint which must be considered. The tonsil surface
exhibits complex geometry but can be thought of effectively as a
large 2-dimensional surface. If infection can only take place
between neighboring epithelial cells, then infection is confined to a
growing 2-dimensional disc. The radius of this disc depends on the
number of rounds of neighbor to neighbor infections, i.e. the
length of time the infection has been spreading. Since the area of a
disc grows with the square of its radius, then the number of
infected cells should only grow in proportion to the time squared.
This means that strict neighbor-to-neighbor contact infection will
not support exponential growth. To maintain exponential
expansion virus would have to spread to targets beyond those in
proximal contact but, this virus would normally be removed by
neutralizing antibody. However, Tugizov et al have shown the in
vitro development of epithelial plaques through the cell to cell
spread of infectious virus via a mechanism involving tightly
connected lateral membranes, which is time dependent [37] and
resistant to neutralizing antibody [38]. In addition they have
shown in vitro that EBV can rapidly spread in epithelium by
transcellular transcytosis potentially allowing the virus to spread
rapidly beyond the adjacent cells allowing exponential expansion
of the plaque (Sharof Tugizov personal communication).
A further result from the CDF analysis is that the slopes are
similar but the range of shedding is different between subjects.
This means that the exponential expansion of the plaques is being
initiated at a different size for each subject but once started is
constant between subjects. This fits nicely with the idea that very
small numbers of B cells are releasing virus that initiates plaque
formation and the number of epithelial cells that initially become
infected is dependent on the particular subject. This variation
could be introduced simply based for example on the efficacy of
the neutralizing antibody each subject produces. A soon as
epithelial cell infection is achieved the growth of the resulting
plaque becomes subject independent again consistent with the
results of Tugizov et al that epithelial infection is not affected by
neutralizing antibody. If we assume that the lowest value for each
subject approximates the initial size of the plaques then we can
estimate (assuming an epithelial cell burst rate of 6.2610
5 per cell
per day) that the initial infection ranges between ,0 and 5
epithelial cells. We have estimated above that the plaques grow for
a maximum of one week and then survive stably for maximally
another week and that there are on average about 3 plaques. If
Figure 7. Adjusted R
2 values for simulations of plaque. A simulation was performed where infectious plaques were initiated randomly,
allowed to grow exponentially and randomly sampled 25 times (see Text S1 and Figure S2). This data was then plotted as a CDF and the adjusted R
2
estimated for the best fit straight line to the data. This process was repeated 100 times for each of the plaque numbers indicated and the resulting R
2
values plotted as a CDF. The red line indicates the lowest (0.88), the green line the 7
th lowest (0.94) and the blue line the median R
2 for our 8 subjects
(see Table 2).
doi:10.1371/journal.ppat.1000496.g007
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average only about 3 such B cells are generated in the Waldeyer’s
ring every 1 to 2 weeks or 1 cell every 2 to 5 days. Although this
seems extremely low it is consistent with our previous findings
([26] and Box 1). As described in Box 1 a screen of tonsils for
expression of the immediate early lytic gene BZLF1 suggested that
on average around 1 B cell every two days completes the lytic cycle
(see Box 1 for the calculation) a result in remarkable concordance
with the estimate from the CDF analysis.
Another insight from the CDF analysis is that the exponential
expansion is arrested at random time intervals to generate the
simple linear step ladders observed in Figure 4. Two explanations
seem possible/likely. The first is that the heterogeneous structure
of the epithelium imposes a random sized barrier on the
expansion. This barrier could take the form of cells that were
not infectable by EBV or otherwise prevented the virus from
spreading. However this would require the epithelial cells to
continue shedding relatively stable quantities of virus for several
hours/days. Continuous virus production for several days without
dying has not been documented for EBV in vitro however, we
have virtually no information about EBV replication in vivo and
such behavior has been described for another herpesvirus CMV
[39,40].
The other process that could interrupt exponential expansion
randomly over time could be the cytotoxic T cell response. It has
been shown that tonsils contain large numbers of EBV specific
CTL [14]. Often .1% of CD8 T cells in the tonsil are specific for
EBV lytic antigens. That study suggested ,10% of these CTL
were activated at any given time indicating an ongoing immune
response. The random log size distribution of the plaques could
then simply reflect the random probability that a CTL will
encounter the exponentially growing plaque over time and destroy
it. This, at least in part, answers the question of why the virus is
able to continuously replicate in Waldeyer’s ring with impunity
despite a persistent ongoing CTL response. A further contributing
factor could be that the virus is known to posses immune evasion
mechanisms that could delay or help evade the CTL response.
These include an IL-10 homologue that suppresses the CTL
response and gene products that interfere with antigen presenta-
tion (reviewed in [41]). Presumably if small numbers of plaques are
regularly being seeded from B cells these evasion mechanisms must
be effective enough to allow the plaques to grow and survive for
several days. Indeed the relatively stable short term shedding we
Figure 8. The variation in virus shedding into saliva over time
is consistently seen in clarified and DNase treated prepara-
tions. Solid line=Saliva was pretreated with DNase to remove
unencapsidated viral DNA. Broken line=Saliva was clarified by
centrifugation and then treated with DNase. Data is shown for three
different subjects (A–C).
doi:10.1371/journal.ppat.1000496.g008
Table 3. Most saliva derived virions are DNase resistant unlike
those derived from cell lines.
Virus Source % DNase resistant
Ave.* SD
B95-8 17 4.5
Akata 4 3.5
Saliva 62 12
Spun Saliva 59 5.5
*The average was derived from 3 independent measurements for Akata and
B95-8 cell lines and from measurements for 3 individuals each measured
independently twice. See Figure S3 for an example from one subject.
doi:10.1371/journal.ppat.1000496.t003
Table 4. Most viral DNA in saliva does not bind to B or
epithelial cells.
Absorption
Low # (5610
3)
virus added
High # (5610
5)
virus added
# virions bound # virions bound
Akata AGS Akata AGS
#1 624 833 1.6610
5 1.4610
5
#2 142 76 2.5610
4 1.7610
4
#3 64 4 6.0610
3 3.6610
3
#4 13 10 4.3610
3 2.0610
3
#5 24 0 1.4610
3 1.0610
3
#6 0 0 8.5610
2 9.8610
2
% unbound 98 98 96 97
A low and high amount of saliva virus was subjected to repeated absorption
with the B cell line Akata and the epithelial line AGS. The amount of bound virus
was assessed after each absorption. Note that .95% of the virus remained
unbound.
doi:10.1371/journal.ppat.1000496.t004
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where the CTL response is only able to contain the spread of the
plaque, it taking several days to finally eliminate it.
If we are predicting that EBV is shed via epithelial plaques
that range in size up to 10
5 cells why have they not been observed
in immunohistochemical studies of tonsils? The answer almost
certainly relies on chance since our analysis predicts that plaques
in the range of 10
4 to 10
5 cells are only present ,10% of the time
in a random sampling of subjects. Furthermore, these cells are
likely contained within a single plaque in the entire Waldeyer’s
ring. Therefore our results predict that it would take exhaustive
and comprehensive analysis of multiple tonsils to have a chance of
seeing an infected plaque of epithelial cells.
In summary, the dynamics of EBV shedding seem to favor a
model (Figure 9) where single B cells sporadically initiate EBV
replication in Waldeyer’s ring. The resultant virus seeds a local
infection of epithelial cells that grows exponentially, for no more
than 7 days, into an infected plaque. Plaque creation occurs at a
rate such that there are 1 to 3 plaques of lytic epithelial cell
infection at any one time. The size of these plaques depends on the
initial number of epithelial cells infected and the ability of the
infection to spread and grow. The size is ultimately bounded
randomly either by the structural constraints of the epithelium
and/or the efficacy of the immune response. Once the plaque has
reached its mature size it produces, for a brief time (up to 7 days), a
constant rate of cells that initiate lytic replication probably
representing a balance between infectious spread and immune
containment. This continues for a few days until the plaque ceases
production presumably due to destruction by the cellular immune
response.
Our results also relate to conclusions drawn previously by other
groups. A long standing claim in the EBV field is that the level of
infected cells in the blood correlates with the level of virus
shedding in saliva [11]. We failed to confirm this finding both
between and within individuals. Furthermore this discrepancy
cannot be accounted for by the fact that we have used PCR to
detect the virus whereas the previous study used a biological assay.
We found no correlation whether we measured total shed
genomes, DNase resistant genomes (virions) or viral binding.
During the course of these studies we observed that, unlike virus
produced by cell lines, the majority of saliva virus is encapsidated
Figure 9. Schematic representation of the proposed model from this study. EBV infected mBLat that return to the Waldeyer’s ring (tonsils
and adenoids) undergo plasma cell differentiation and initiate viral replication. In a typical healthy carrier the number of such cells at any one timei s
#50 and therefore insufficient to account for either the absolute level or the variation in shedding that we have observed over time. Virus released
from the plasma cells infects the epithelium of Waldeyer’s ring where it forms a plaque containing anywhere from 1 to 10
5 infected epithelial cells
thus amplifying the amount of shed virus. Variability in the final size and stability of these plaques accounts for the high levels and variability of virus
shedding and is probably a function of the initial seed of infected epithelial cells, the epithelial structure, and the immune response. Virus from the
plaque is continuously shed into the saliva for several days providing a continuous stream of virions in the saliva that is replaced#every 1 to
2 minutes.
doi:10.1371/journal.ppat.1000496.g009
Box 2. Epithelial cell infection can account for
the observed level of virus shedding.
The surface area, including the crypts, of a palatine tonsil is
reported to be 340 cm
2 [34].
A palatine tonsil constitutes approximately one twelfth of
Waldeyer’s ring [34].
Therefore, the total epithelial cell surface area of
Waldeyer’s ring is ,4,080 cm
2.
From monolayer cultures of primary tonsil epithelium [28]
we estimate that 1 cm
2 of confluent epithelium contains
,2610
5 epithelial cells.
Therefore, 4,080 cm
2 contains ,10
9 epithelial cells.
Since in actual tonsils the epithelium is multilayered the
total number of epithelial cells in Waldeyer’s ring
approximates ,10
10.
In primary cultures of tonsil epithelium we have seen
,0.01% of the cells to be lytically infected with EBV [28].
Therefore, ,10
6 epithelial cells may be lytic in the entire
Waldeyer’s ring of these subjects.
Given an average burst size for epithelial cells of 6.2610
5
and assuming a burst time of 24 hours:
Typical virion production from the epithelium could be
<6.2610
11 genomes per day. E.
Comparing line E with line D in Box 1 it is apparent that
the epithelium could account for the levels of virus
shedding we have measured.
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(,5%) consistent with previous observations that most of the virus
may be coated with neutralizing antibodies [21].
In conclusion, detailed studies of virus shedding indicate that
healthy carriers of EBV consistently shed large amounts of the
virus into saliva. Furthermore the dynamics of shedding suggest a
crucial role for epithelial cells in amplifying the amount of shed
virus. However in healthy carriers, although most of the shed virus
is intact, very little of it is infectious.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Tufts Medical School and Tufts
Medical Center (IRB study #731). All subjects provided written
informed consent for the collection of samples and subsequent
analysis.
Cells and cell lines
Whole blood samples were obtained from health volunteers.
PBMCs were isolated by Ficoll Hypaque centrifugation and B cells
were purified by negative selection with a StemSep column
following the manufactures instructions. The efficiency of
purification was checked by staining for CD20 and FACS analysis.
B cells were always 90–96% pure. Memory B cells were isolated
from purified B cells using a MoFlo FACS sorter, based on
staining with anti-CD27-FITC (memory B cell marker) and anti-
CD20-PE (pan B cell marker).
The EBV positive lymphoblastoid line IB4 (gift from Dr Elliot
Kieff) was used as a positive control and the murine CB59 T cell
line (gift from Dr Miguel Stadecker) as negative control for EBV
DNA PCR. The EBV negative Burkitt lymphoma line Akata and
the gastric carcinoma cell line AGS (gifts from Dr Lindsey Hutt-
Fletcher) were used as target cells for binding assays. The EBV
positive B95-8 marmoset B cell (gift of Dr Elliot Kieff), Akata
2A8.1 (gift of Dr. Jeff Sample), AGSBX1 gastric carcinoma (gift
from Dr Lindsey Hutt-Fletcher) and Hone1Akata nasopharyngeal
carcinoma (gift from Dr Ron Glaser) cell lines were used for
measuring the viral burst size.
Real time PCR
EBV genomes were detected by a Real time Taqman DNA
PCR assay for the W repeat region as described previously [4].
This assay can detect a single copy of the EBV genome in a
background of 10
6 EBV-negative cells and a single virion in 0.1 ml
of saliva (not shown). PCR was performed in a volume of 25 mlo n
the ABI Prism 5700 (Perkin Elmer) or MyIQ System (BioRad).
Thermal cycling was initiated with a denaturation step at 95uC for
3 min, and continued with 50 cycles of amplification at 95uC for
15 seconds and 60uC for 1 minute. For each reaction, 5 mlo f
DNA template was added to a master mix containing 12.5 mlo f
Universal TaqMan Master Mix (Applied Biosystems or BioRad)
and 2.5 ml each of the forward primer, reverse primer and
flurogenic probe. The primers used were AGTGGGCTTG-
TTTGTGACTTCA (forward) and GGACTCCTGGCGCTCT-
GAT (reverse) and the flurogenic probe was 6-FAM-TTACG-
TAAGCCAGACAGCAGCCAATTGTC-TAMRA.
To control for variation in sampling over time, the levels of viral
DNA in saliva samples were normalized to the levels of
endogenous cellular DNA based on detection of the bcl-2 gene.
Bcl-2 Sybr Green Real time PCR was performed in a volume of
25 ml. For each reaction, 5 ml of DNA template from shedding
assay was added to a master mix containing 12.5 ml of Sybr Green
Master Mix (BioRad) and 2.5 ml each of the forward, reverse
primers and water. The primers used were CTTTAGAGAG-
TTGCTTTACGTG (forward) and TCCATATTCATCACT-
TTGACAA (reverse). Thermal cycling was initiated with a
denaturation step at 95uC for 3 minutes and continued with 45
cycles of amplification at 95uC for 15 seconds, 55uC for
15 seconds, 72uC for 30 seconds, and 83uC for 10 seconds. This
was followed by melting curve analysis at 95uC for 1 minute, 55uC
for 1 minute, and 80 cycles of 55uC for 30 seconds.
To assess the efficiency of DNase treatment samples were
assayed for the presence of cellular DNA by Real time Sybr Green
PCR for the b-actin gene. PCR was performed in a volume of
25 ml. For each reaction, 5 ml of DNA template from saliva
samples was added to a master mix containing 12.5 ml of Sybr
Green Master Mix (BioRad) and 2.5 ml each of the forward,
reverse primers and water. The primers used were GCG-
GGAAATCGTGCGTGACATT and GATGGAGTTGAAGG-
TAGTTTCGTG. Thermal cycling was initiated with a denatur-
ation step at 95uC for 3 minutes and continued with 40 cycles of
amplification at 95uC for 15 seconds, 60uC for 20 seconds, and
72uC for 25 seconds. This was followed by melting curve analysis
at 95uC for 1 minute, and 80 cycles of 58uC for 20 seconds.
Frequency of infected B cells
The frequency of latently infected cells in purified whole B or
memory B cell populations was measured by limiting dilution
analysis of the cell population followed by detection of EBV
infected cells by EBV specific Real time Taqman DNA PCR for
the W repeat sequence as described above and in [4]. This PCR
can reproducibly detect a single copy of the viral genome.
Virus shedding
Saliva sample were obtained from health volunteers. Except
where noted, saliva samples were collected by mouth rinse and
gargling with 5 ml of fluid. We have compared the efficiency of
recovery using isotonic saline, PBS, RPMI 1640 and simple spring
drinking water. We found that the recovery of viral DNA was the
same regardless of the fluid used. Thereafter rinses were always
performed with water and the salinity and pH adjusted by
immediate addition of 106PBS. For some experiments the saliva
was clarified by centrifugation at 1500 rpm for 5 minutes at 4uC
in an Allegra 6 bench top microfuge (Beckman Coulter) and/or
treated with DNase (see below). Samples were stored at 280uC
until all time points were collected and then analyzed simulta-
neously. In control experiments we found no detectable change in
recovery of viral DNA after such storage periods.
100 ul of the saliva sample were digested overnight with
proteinase K (PK) (Invitrogen, 0.5 mg/ml final concentration) at
55uC in a 96-well plate (8–10 replicate wells per subject per time
point). 5 ul of the digested sample was used as template for EBV
DNA PCR as described after deactivating the PK by heating to
95uC for 10 minutes. The amount of viral DNA in each replicate
was then estimated from a standard curve generated by serial
dilution (in duplicate) of an aliquot from a defined B958 culture
supernatant. The amount of viral DNA in this supernatant was
previously defined by limiting dilution analysis and the superna-
tant aliquoted and stored frozen The average value from the 8–10
replicates was then used to calculate the absolute number of
virions in the 5 ml saliva sample.
DNase treatment
DNase mix was pre-made and contained DNase (Invitrogen),
106DNase Buffer and water. 10 ul of DNase mix was added per
Dynamics of EBV Shedding
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unless otherwise noted. DNase treatment was performed at room
temperature for 30 minutes. DNase was deactivated by adding
EDTA (2 mM) followed by incubation at 70–80uC for 30 minutes.
Under these conditions virion DNA, defined as DNase resistant
viral sequences, were stable for at least 1 hour whereas essentially
all free cellular DNA (.99% of b-actin) was digested within
15 minutes (see Figure S3).
Binding assay
The EBV negative Akata cell line and gastric carcinoma cell line
AGS were used as target cells at 10
6 cells per ml. AGS cells were
placed in suspension by brief treatment with trypsin. Eight
replicates of each binding condition were set up in a 96-well plate.
Saliva samples with or without prior clarification by centrifugation
and with or without DNase treatment were added into wells of
target cells. The binding reaction was then performed at 37uC for
30 minutes. Cells were then pelleted by centrifugation at
1500 rpm at 4uC for 10 minutes. Cell pellets were washed 3
times with 100 ul of PBSA (0.5% BSA in PBS) per well and
subsequently PK-digested at 55uC overnight. A serial dilution of
B958 supernatant (EBV-producing cell line) with known numbers
of virions was used as standard for the binding assay. Saliva of an
EBV (-) subject and PBSA added onto target cells were used as
negative controls.
Measurement of viral burst size
For induction of lytic replication, the B95-8 B cell line was
stimulated with PMA at 20 ng/ml,the Akata 2A8.1 B cell line was
stimulated with a combination of PMA (20 ng/ml) and Ionomycin
(1 or 10 ug/ml) [42], the AGSBX1 epithelial line was stimulated
witha combination ofPMA(30 ng/mL)andButryicAcid (2.5 mM)
[29] and the Hone1Akata epithelial line with PMA (40 ng/mL) and
Butryic Acid (3 mM) [43]. Prior to stimulation, the cell lines were
synchronized by reseeding in media overnight at 5610
5/ml for B
cells and 3–56106/ml for epithelial cells. B cells were harvested at
48 hours for intracellular VCA (viral capsid antigen) staining and
FACS analysis and culture supernatants were harvested for EBV
specific DNA PCR at 72 hours. Epithelial cells were harvested for
VCA staining after 96 hours and for PCR from 96–174 hours.
For intracellular VCA staining, harvested cells were washed once
with PBS and pelleted by centrifugation at 1300 rpm for 7 minutes
at 4uC. Cell pellets wereresuspended at 10
6 cells per 200 ul of fixing
buffer (4% formaldehyde in PBS) and incubated at room
temperature for 10 minutes. Once the cells were fixed, 1 ml of
PBS was added per 10
6 cells and the cell pellets were dissociated by
vortexing, and then re-pelleted by centrifugation. The PBS wash
step was repeated again before resuspension into 200 ul of
permeabilization buffer (8% FBS, 0.02% NaN3, 0.04% Saponin,
2%Goat SeruminPBS)per10
6 cells,followedbyincubationat 4uC
for 30 minutes. All staining was performed in FACS tubes at 10
6
cells per tube. Cells were stained with either 200 ul of mouse IgG2a
isotype control (Caltag) or 200 ul of mouse anti-VCA-IgG2a
antibody (Capricorn) per 10
6 cells diluted 1:1000 in permeabiliza-
tion buffer and incubated at 37uC for 30 minutes. The cells were
then washed twice with 1 ml wash buffer (8% FBS, 0.02% NaN3,
0.04% Saponin in PBS) and pelleted. Next, cells were resuspended
in 100 ul of a 1:10,000 dilution of Alexa Fluor 488 or 647
conjugated goat anti-mouse IgG (H+L) (Molecular Probes) diluted
in permeabilization buffer and incubated at 37uC for 30 min in the
dark. Then, the cells were washed twice by vortexing in 2 ml of
wash buffer and pelleted by centrifugation. Finally, cells were
resuspended in 300 ul of FACS buffer (8% FBS, 0.02% NaN3 in
PBS) for analysis on a FACS Caliber flow cytometer or 60 ul of
FACS buffer for analysis on an Amnis ImageStream with IDEA
analytical software to confirm the authenticity of the staining.
EBV DNA content of the culture supernatants was measured by
DNA PCR with or without DNase treatment as described for the
saliva samples.
Simulations and statistical analysis
Simulations and statistical analysis (CDF and adjusted R
2 linear
regression analysis) were performed with MatLab software. To
study linearity in the expected CDF for a limited number of data
points with various numbers of hypothetical plaques a simulation
was run. In this simulation plaques were arbitrarily assigned to
undergo exponential growth. Growth of the plaques was initiated
randomly and the sum of infected cells assessed at 20 random time
points picked using a Monte Carlo algorithm. For details see
Figure S2 and associated text.
Supporting Information
Figure S1 Saliva virus is not depleted even after multiple large
volume mouth gargles and rinses.
Found at: doi:10.1371/journal.ppat.1000496.s001 (0.02 MB PDF)
Figure S2 Simulated CDF’s for infections involving various
numbers of hypothetical plaques sampled randomly 20 times.
CDFs for two simulations are shown for each number of plaques
together with their best-fit linear approximation. The number of
plaques simulated (n) and the resulting value for the adjusted R
2 are
given above each plot. For a detailed discussion see following text.
Found at: doi:10.1371/journal.ppat.1000496.s002 (0.05 MB PDF)
Figure S3 The majority of EBV DNA is DNaseresistant whereas
essentially all cellular DNA is sensitive.
Found at: doi:10.1371/journal.ppat.1000496.s003 (0.03 MB PDF)
Figure S4 There is no correlation between the frequency of
infected mBlat (FOI) in the blood and the levels of shed virus in
four different types of saliva sample preparations from 5 subjects.
Found at: doi:10.1371/journal.ppat.1000496.s004 (0.02 MB PDF)
Figure S5 There is no correlation between the frequency of
infected mBlatin the blood (FOI) and the levels of virus that binds
to B cells (Akata) or epithelial cells (AGS) in two different types of
saliva sample preparations from 5 subjects.
Found at: doi:10.1371/journal.ppat.1000496.s005 (0.03 MB PDF)
Table S1 There is no correlation between the frequency of
infected mBlat (FOI) in the blood and the levels of virus shed into
saliva. This data is represented graphically in Figure 5.
Found at: doi:10.1371/journal.ppat.1000496.s006 (0.02 MB PDF)
Text S1 Empirical CDF of shedding suggests there are at most 3
plaques at any one time.
Found at: doi:10.1371/journal.ppat.1000496.s007 (0.06 MB PDF)
Text S2 Why we have not observed the growth phase.
Found at: doi:10.1371/journal.ppat.1000496.s008 (0.04 MB PDF)
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